Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 22kWORD 20k
17 May 2019
Answer given by Mr Oettinger on behalf of the European Commission
Question reference: E-001254/2019

The Commission has been in frequent contact with the European Medicines Agency (EMA) over the Agency’s efforts to find a new tenant for the London building and to keep the related costs under control.

EMA signed its rent contract in 2011 without a break clause, bearing in mind that negotiating such a break clause would have increased the rental costs considerably. The absence of a break clause in the rent contract was a conscious choice to achieve savings, at a time when a potential United Kingdom withdrawal was not under discussion. On this basis the European Parliament and the Council (‘the budgetary authority’) approved EMA’s building file in 2011.

Following the submission of its request to the budgetary authority on 4 March 2019, the EMA obtained the European Parliament’s approval on 18 March 2019 and Council approval on 2 April 2019, to enter into a sub-lease contract for the London building. Negotiations with the landlord and the sub-tenant are currently ongoing.

Last updated: 20 May 2019Legal notice